|
|
| | Lacnotuzumab Basic information |
| Product Name: | Lacnotuzumab | | Synonyms: | Lacnotuzumab;Research Grade Lacnotuzumab;Lacnotuzumab (anti-M-CSF) | | CAS: | 1831128-32-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Lacnotuzumab Structure]() |
| | Lacnotuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Lacnotuzumab Usage And Synthesis |
| Uses | Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis[1][2]. | | in vivo | Lacnotuzumab neutralizes recombinant and serum-derived forms of cynomolgus CSF-1, but it does not recognize rodent or rabbit CSF-1[2]. | | References | [1] Kuemmel S, et, al. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Jan 1;28(1):106-115. DOI:10.1158/1078-0432.CCR-20-3955
[2] Pognan F, et, al. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442. DOI:10.1124/jpet.118.254128 |
| | Lacnotuzumab Preparation Products And Raw materials |
|